|Dr. Peter Barrett||Exec. Chairman||25.15k||N/A||1953|
|Dr. José Carlos Gutierrez-Ramos Ph.D.||Advisor||817.27k||N/A||1963|
|Dr. Aoife M. Brennan MB, BCh, BAO, MMSc||Pres, CEO & Director||N/A||N/A||1976|
|Prof. Timothy K. Lu||Co-Founder||N/A||N/A||N/A|
|Dr. James J. Collins||Co-Founder||N/A||N/A||1965|
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. The company also has a clinical collaboration with Hoffman-La Roche Ltd. to evaluate SYNB1891 in combination with PD-L1 checkpoint inhibitor in patients with advanced solid tumors. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Synlogic, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 8.